){kind=small}
Solventum: A Hidden Breakup Story In Healthcare
Solventum has a few good businesses, but the market is treating it as a complicated company. Its main parts are MedSurg, Dental, HIS, and a smaller Water / All Other. The thesis says the stock looks much cheaper than the value of the parts. The business could be worth about $166.6 per share based on SOTP analysis. The main idea is to keep MedSurg as the core business and see more value in the other parts on their own.
SOLV or HQY: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical Services sector have probably already heard of Solventum (SOLV) and HealthEquity (HQY). But which of these two stocks presents investors with the better value opportunity right now?
Why Solventum (SOLV) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Hold Solventum Stock in Your Portfolio Now
SOLV rides on strong segment demand, innovation push and cost savings plan, but tariffs and rising input costs cloud margin outlook.
Solventum Corporation (SOLV) Presents at 2026 KeyBanc Capital Markets Healthcare Forum Transcript
Solventum Corporation (SOLV) Presents at 2026 KeyBanc Capital Markets Healthcare Forum Transcript
Solventum (SOLV) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Solventum: Improvements Come Slow
Solventum shares have traded sideways post-spin, as investors digest separation impacts, stranded costs, and recent capital allocation moves. Despite a $4.1B divestment and targeted $500M cost savings, 2025 results showed minimal free cash flow and only modest earnings growth. 2026 guidance calls for 2-3% organic sales growth and adjusted EPS of $6.50, but free cash flow remains weak at ~$200M.
Solventum Stock Down Despite Q4 Earnings & Revenues Beat, Margins Down
SOLV's Q4 earnings and revenues beat estimates, driven by organic growth across MedSurg, Dental and HIS, despite margins declined.
Solventum Corporation (SOLV) Q4 2025 Earnings Call Transcript
Solventum Corporation (SOLV) Q4 2025 Earnings Call Transcript
Solventum (SOLV) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Solventum (SOLV) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Solventum (SOLV) Surpasses Q4 Earnings and Revenue Estimates
Solventum (SOLV) came out with quarterly earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.5 per share. This compares to earnings of $1.41 per share a year ago.
Solventum beats quarterly estimates on strong demand for surgical products
Medical device maker Solventum on Thursday beat Wall Street estimates for the fourth quarter, helped by strong demand for its wound care and sterilization products.
